title: Intracavitary cisplatin therapy for pediatric malignancies.
abstract: BACKGROUND
  Local control is essential for the successful treatment of pediatric solid tumors. Complete excision is often not possible and local control therapies are limited. Intracavitary cisplatin (IC-CDDP) may be utilized to supplement local control. The aim of the study was to determine the toxicity and efficacy of locally instilled intracavitary cisplatin in patients with recurrent tumors in closed body cavities.
  
  
  METHODS
  From 2001 to 2009, 12 patients (1-20 years) with recurrent or unresectable malignant tumors were treated with IC-CDDP. Nine had pulmonary lesions. Three patients had abdominal tumors. CDDP (200 mg/m(2)) was instilled by chest tube or Tenckhoff catheter. Patients were shifted every 15-30 min to allow distribution. After 4 hr, residual was drained by gravity. In 10/13 courses, sodium thiosulfate (STS) was administered to prevent nephrotoxicity. Three other patients received amifostine.
  
  
  RESULTS
  Malignant pleural effusions resolved in 5/7 patients. This response was temporary in three patients. No patients had ascites prior to treatment. Three patients are alive and disease-free, 18 months, 4 years, and 6 years from treatment. They also had surgery and chemotherapy. Transient renal toxicity was noted in most patients. One patient, treated with amifostine, had persistent renal dysfunction.
  
  
  CONCLUSIONS
  IC-CDDP was effective in treating malignant pleural effusions and may be a palliative option for refractory disease. Long-term survival was achieved in two patients, treated at first diagnosis. The benefit of IC-CDDP in these patients is difficult to assess. Renal dysfunction is usually mild, and typically resolves, but warrants preventive measures with IC-CDDP therapy.
authors.affiliation: Aflac Cancer Center and Blood Disorders Services, Division of Pediatric Hematology/Oncology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
authors.forename: Howard M
authors.initials: HM
authors.lastname: Katzenstein
authors.forename: Sarah
authors.initials: S
authors.lastname: Petricca
authors.forename: Richard
authors.initials: R
authors.lastname: Ricketts
authors.forename: Karen
authors.initials: K
authors.lastname: Wasilewski-Masker
authors.forename: Christie
authors.initials: C
authors.lastname: Powell
authors.forename: Louis
authors.initials: L
authors.lastname: Rapkin
authors.forename: Bradley
authors.initials: B
authors.lastname: George
authors.forename: William G
authors.initials: WG
authors.lastname: Woods
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Olson
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001201:Ascites / Q000188:drug therapy / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D035422:Pleural Cavity; D016066:Pleural Effusion, Malignant / Q000188:drug therapy / Q000209:etiology; D013899:Thoracic Neoplasms / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin